Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To determine the EFFICACY and the SAFETY PROFILE and TOXICITY of Zarnestra® in the treatment
of patients with previously treated mantle cell lymphoma not appropriate for autologous bone
marrow transplantation. 27 evaluable subjects will be enrolled for an analysis in 2 stages
(11 for the first stage, 16 for the second).
Patients who receive at least one dose of Zarnestra® and have at least one post-baseline
response assessment of discontinued study frug for early progression are evaluable. Subjects
not evaluable for response will be replaced, up to 35 patients.